Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the…
• Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® • Travere to receive up to $445 million with $210 million upfront and up to $235 million in…